ARDS - Aridis Pharmaceuticals, Inc.
| Previous Close | 9.27 |
| Open | 9.41 |
| Bid | 8.52 x 900 |
| Ask | 12.00 x 2200 |
| Day's Range | 9.32 - 9.41 |
| 52 Week Range | 7.59 - 13.85 |
| Volume | 1,399 |
| Avg. Volume | 4,295 |
| Market Cap | 75.56M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.25 |
- PR Newswire•12 days ago
Aridis Pharmaceuticals Announces First Quarter 2019 Results
SAN JOSE, Calif. , May 14, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- Zacks•2 months ago
Will Aridis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Aridis Pharmaceuticals.
- Zacks•2 months ago
Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why
Aridis Pharmaceuticals (ARDS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire•2 months ago
Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
SAN JOSE, Calif. , March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- Simply Wall St.•4 months ago
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals
Attractive stocks have exceptional fundamentals. In the case of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), there's is a company with strong financial health as well as a excellent growth outlook. Below, I've Read More...
- American City Business Journals•5 months ago
Here are the winners and losers from Bay Area's IPO class of 2018
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
- PR Newswire•5 months ago
AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
- Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer - Study Being Performed in Collaboration ...
- American City Business Journals•6 months ago
This year's Bay Area IPO batch remains up 44% despite market turbulence
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
- PR Newswire•6 months ago
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
- CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million - FDA grants Fast-Track and QIDP Designations for AR-501, enabling future ...
American City Business Journals•6 months agoHealth Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.
- GlobeNewswire•6 months ago
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•6 months ago
Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview
- Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market - Maintained the pace of patient enrollment of the AR-105 global Phase 2 clinical study; on track for ...
- PR Newswire•7 months ago
Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
- Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine - Potential breakthrough approach ...
- PR Newswire•8 months ago
Aridis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
SAN JOSE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully ...
- PR Newswire•8 months ago
Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates
- New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio SAN JOSE, Calif. , Sept. 24, ...
- PR Newswire•9 months ago
Aridis Pharmaceuticals Announces Pricing of Initial Public Offering
SAN JOSE, Calif., Aug. 13, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aridis. In addition, Aridis has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Aridis.
